Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Completed 9Recruiting 5Terminated 2Withdrawn 1Unknown 1Approved for marketing 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 1CNS 1

Conditions

Carcinoma, Hepatocellular 1Brain Neoplasms 1

Interventions

Cyclophosphamide 390Carboplatin 344Gemcitabine 332pembrolizumab 329Cisplatin 328Paclitaxel 297Radiotherapy 296Docetaxel 286Bevacizumab 253Rituximab 234Capecitabine 223Nivolumab 220Dexamethasone 206Fluorouracil 190fludarabine 177Oxaliplatin 177Pemetrexed 153Doxorubicin 153Irinotecan 148Leucovorin 144Etoposide 144Cytarabine 133Cetuximab 129Bortezomib 129fludarabine phosphate 128Lenalidomide 126Erlotinib Hydrochloride 120Filgrastim 119Temozolomide 113Radiosurgery 113

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Gadolinium × Clear all
NCT00659126 2023-09-07

Ferumoxytol- and Gadolinium-Labeled MRI in Measuring Tumors Before or After Treatment in Patients With Primary or Metastatic Brain Tumors

OHSU Knight Cancer Institute

Phase 2 Terminated
40 enrolled 8 charts
CNS

Brain Neoplasms

NCT02057874 2018-07-11

3-Tesla MRI Response to TACE in HCC (Liver Cancer)

Vanderbilt-Ingram Cancer Center

Phase NA Terminated
2 enrolled 4 charts
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡